Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem

References

• Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370.
   PubMed Web of Science ®Google Scholar
• Goldberg R, Dennen P. Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis. 2008;15(3):297–307.
   PubMed Web of Science ®Google Scholar
• Hoste EAJ, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008;36(4 Suppl):S146–S51.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330–1336.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734–744.
   PubMed Web of Science ®Google Scholar
• Pratt JA, Stricherz MK, Verghese PS, et al. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population: piperacillin-tazobactam induced nephrotoxicity. Pediatr Blood Cancer. 2014;61(2):366–368.
   PubMed Web of Science ®Google Scholar
• Moenster RP, Linneman TW, Finnegan PM, et al. Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect. 2014;20(6):O384–9.
   PubMed Web of Science ®Google Scholar
• Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin–tazobactam compared to those on vancomycin and cefepime. CLINID. 2017;64(2):116–123.
   PubMed Web of Science ®Google Scholar
• Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12–20.
   PubMed Web of Science ®Google Scholar
• Hammond DA, Smith MN, Li C, et al. Systematic review and Meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017;64(5):666–674.
   PubMed Web of Science ®Google Scholar
• Jeon N, Staley B, Klinker KP, et al. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function. Int J Antimicrob Agents. 2017;50(1):63–67.
   PubMed Web of Science ®Google Scholar
• Rutter WC, Cox JN, Martin CA, et al. Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime. Antimicrob Agents Chemother. 2017;61(2):e02089–16.
   PubMed Web of Science ®Google Scholar
• Al Yami MS. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. J Infect Public Health. 2017;10(6):770–773.
   PubMed Web of Science ®Google Scholar
• Rutter WC, Burgess DS. Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin. Antimicrob Agents Chemother. 2018;62(7):e00264-18. Available from: http://aac.asm.org/cgi/pmidlookup?view=long&pmid=29712661
   Web of Science ®Google Scholar
• Robertson AD, Li C, Hammond DA, Dickey TA. Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin-tazobactam or meropenem. Pharmacotherapy. 2018;38(12):1184–1193.
   PubMed Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84.
   PubMedGoogle Scholar
• Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102(3):459–469.
   PubMed Web of Science ®Google Scholar
• King DW, Smith MA. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro. 2004;18(6):797–803.
   PubMed Web of Science ®Google Scholar
• Mannaerts L, Van der Wurff AA, Wolfhagen FHJ. Interstitial nephritis attributed to treatment with piperacillin-tazobactam and with ciprofloxacin. Ned Tijdschr Geneeskd. 2006;150(14):804–807.
   PubMedGoogle Scholar
• Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy. 2014;34(7):653–661.
   PubMed Web of Science ®Google Scholar
• Giuliano CA, Patel CR, Kale-Pradhan PB. Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis. Pharmacotherapy. 2016;36(12):1217–1228.
   PubMed Web of Science ®Google Scholar
• Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract. 2017;30(2):209–213.
   PubMedGoogle Scholar
• Balcı C, Uzun Ö, Arıcı M, et al. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents. 2018;52(2):180–184.
   PubMed Web of Science ®Google Scholar
• Karino S, Kaye KS, Navalkele B, et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: opportunities for antimicrobial stewardship. Antimicrob Agents Chemother. 2016;60(6):3743–3750.
   PubMed Web of Science ®Google Scholar
• Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68(9):1243–1255.
   PubMed Web of Science ®Google Scholar
• Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34(7):670–676.
   PubMed Web of Science ®Google Scholar
• Rutter WC, Burgess DS. Acute kidney injury in patients treated with IV beta-lactam/beta-lactamase inhibitor combinations. Pharmacotherapy. 2017;37(5):593–598.
   PubMed Web of Science ®Google Scholar
• Cowley MC, Ritchie DJ, Hampton N, et al. Outcomes associated with DE-escalating therapy for methicillin-resistant Staphylococcus aureus in culture-negative nosocomial pneumonia. Chest. 2019;155(1):53–59.
   PubMed Web of Science ®Google Scholar
• Boyce JM, Pop O-F, Abreu-Lanfranco O, et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother. 2013;57(3):1163–1168.
   PubMed Web of Science ®Google Scholar
• Baby N, Faust AC, Smith T, et al. Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia. Antimicrob Agents Chemother. 2017;61(4):e02432-16. Available from: http://aac.asm.org/cgi/pmidlookup?view=long&pmid=28137813
   PubMed Web of Science ®Google Scholar
• Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of methicillin-resistant staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic Meta-analysis with antimicrobial stewardship implications. Clin Infect Dis. 2018;67(1):1–7.
   PubMed Web of Science ®Google Scholar